EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Lowering LDL cholesterol by PCSK9 inhibition: a new era of gene silencing, RNA, and alternative therapies

Mitali Paryani, Nikita Gupta, Sanjay Kumar Jain, Shital Butani

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025

DOI: 10.1007/s00210-025-03826-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Mitali Paryani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacy, Nirma University, Gujarat, 382481, India. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Oligonucleotides, Antisense, Plant Extracts, Proprotein Convertases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 84 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) discovery has added a new paradigm to our understanding of cholesterol homeostasis and lipid metabolism. Since its discovery, PCSK9 inhibitors have become a widely investigated therapeutic class for lipid management in cardiovascular diseases and hypercholesterolemia. Scientists have explored different approaches for PCSK9 inhibition, such as monoclonal antibodies (mAbs), gene silencing and gene editing techniques, vaccines, mimetic peptides, and small molecules. European Medicines Agency (EMA) and United States Food and Drug Administration (US FDA) have approved only three PCSK9 inhibitors, including two monoclonal antibodies and one small interfering ribonucleic acid (siRNA). Despite the efficacy of approved large molecules, high costs and the need for regular injection have limited their adherence to the patient. This review aims to provide an understanding of PCSK9's function in Low-Density Lipoprotein Cholesterol (LDL-C) management, its current treatment, recent advancements, and potential future development of small molecules in the class of PCSK9 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalOligonucleotides, AntisensePlant ExtractsProprotein ConvertasesRNA, Small InterferingAnticholesteremic AgentsHumansCholesterol, LDLCRISPR-Cas SystemsGene SilencingHypercholesterolemiaProprotein Convertase 9Protein Subunit VaccinesRecombinant ProteinsFibronectin Type III Domain

Stichwörter der Autor:innen

CholesterolLow-Density LipoproteinNatural moleculePCSK9 inhibitorStatin intolerant

Substanzen

adnectinAntibodies, MonoclonalCholesterol, LDLOligonucleotides, AntisensePCSK9 protein, humanPlant ExtractsProprotein Convertase 9Proprotein ConvertasesProtein Subunit VaccinesRNA, Small Interfering

Autor:innen und Institutionen

  • Institute of Pharmacy, Nirma University, Gujarat, 382481, India.
  • India Operations, Amneal Pharmaceuticals, Ahmedabad, Gujarat, India.
  • Institute of Pharmacy, Nirma University, Gujarat, 382481, India. shital.butani@nirmauni.ac.in.

Zitieren

APA

Paryani, M., Gupta, N., Jain, S. K., & Butani, S. (2025). Lowering LDL cholesterol by PCSK9 inhibition: a new era of gene silencing, RNA, and alternative therapies. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-03826-4

Vancouver

Paryani M, Gupta N, Jain SK, Butani S. Lowering LDL cholesterol by PCSK9 inhibition: a new era of gene silencing, RNA, and alternative therapies. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-03826-4

BibTeX
@article{Paryani2025,
  author = {Paryani, Mitali and Gupta, Nikita and Jain, Sanjay Kumar and Butani, Shital},
  title = {Lowering LDL cholesterol by PCSK9 inhibition: a new era of gene silencing, RNA, and alternative therapies},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  doi = {10.1007/s00210-025-03826-4}
}
Kostenlos starten →